454 related articles for article (PubMed ID: 27581340)
21. FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.
Flockerzi FA; Roggia C; Langer F; Holleczek B; Bohle RM
Virchows Arch; 2018 May; 472(5):759-769. PubMed ID: 29270870
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.
Englinger B; Kallus S; Senkiv J; Heilos D; Gabler L; van Schoonhoven S; Terenzi A; Moser P; Pirker C; Timelthaler G; Jäger W; Kowol CR; Heffeter P; Grusch M; Berger W
J Exp Clin Cancer Res; 2017 Sep; 36(1):122. PubMed ID: 28882160
[TBL] [Abstract][Full Text] [Related]
23. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
[TBL] [Abstract][Full Text] [Related]
24. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
25. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
[TBL] [Abstract][Full Text] [Related]
26. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
27. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
28. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Weiss J; Sos ML; Seidel D; Peifer M; Zander T; Heuckmann JM; Ullrich RT; Menon R; Maier S; Soltermann A; Moch H; Wagener P; Fischer F; Heynck S; Koker M; Schöttle J; Leenders F; Gabler F; Dabow I; Querings S; Heukamp LC; Balke-Want H; Ansén S; Rauh D; Baessmann I; Altmüller J; Wainer Z; Conron M; Wright G; Russell P; Solomon B; Brambilla E; Brambilla C; Lorimier P; Sollberg S; Brustugun OT; Engel-Riedel W; Ludwig C; Petersen I; Sänger J; Clement J; Groen H; Timens W; Sietsma H; Thunnissen E; Smit E; Heideman D; Cappuzzo F; Ligorio C; Damiani S; Hallek M; Beroukhim R; Pao W; Klebl B; Baumann M; Buettner R; Ernestus K; Stoelben E; Wolf J; Nürnberg P; Perner S; Thomas RK
Sci Transl Med; 2010 Dec; 2(62):62ra93. PubMed ID: 21160078
[TBL] [Abstract][Full Text] [Related]
29. FGFR- gene family alterations in low-grade neuroepithelial tumors.
Bale TA
Acta Neuropathol Commun; 2020 Feb; 8(1):21. PubMed ID: 32085805
[TBL] [Abstract][Full Text] [Related]
30. FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
Bogatyrova O; Mattsson JSM; Ross EM; Sanderson MP; Backman M; Botling J; Brunnström H; Kurppa P; La Fleur L; Strell C; Wilm C; Zimmermann A; Esdar C; Micke P
Eur J Cancer; 2021 Jul; 151():136-149. PubMed ID: 33984662
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
32. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
33. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
35. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.
Ji W; Yu Y; Li Z; Wang G; Li F; Xia W; Lu S
Oncotarget; 2016 Mar; 7(12):15118-34. PubMed ID: 26936993
[TBL] [Abstract][Full Text] [Related]
36. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
37. Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma.
Zheng L; Liu H; Chen L; You X; Lv F; Fan H; Hui Q; Liu B; Wang X
Appl Biochem Biotechnol; 2024 Jan; 196(1):573-587. PubMed ID: 37160564
[TBL] [Abstract][Full Text] [Related]
38. Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
Duch P; Díaz-Valdivia N; Gabasa M; Ikemori R; Arshakyan M; Fernández-Nogueira P; Llorente A; Teixido C; Ramírez J; Pereda J; Chuliá-Peris L; Galbis JM; Hilberg F; Reguart N; Radisky DC; Alcaraz J
Cancer Sci; 2024 May; 115(5):1505-1519. PubMed ID: 38476010
[TBL] [Abstract][Full Text] [Related]
39. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
40. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
